Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection

Journal of Infectious Diseases

Volumn 209, Issue 10, 2014, Pages 1573-1584

  Pereira, Lenore ^a   Petitt, Matthew ^a   Fong, Alex ^b   Tsuge, Mitsuru ^a   Tabata, Takako ^a   Fang Hoonver, June ^a   Maidji, Ekaterina ^c   Zydek, Martin ^a   Zhou, Yan ^c   Inoue, Naoki ^d   Loghavi, Sanam ^e   Pepkowitz, Samuel ^e   Kauvar, Lawrence M ^f   Ogunyemi, Dotun ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f Trellis Bioscience   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

amnion; blood vessels; chorion; congenital; fetus; HCMV; IUGR; placenta; pregnancy; villi

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; INFECTED CELL PROTEIN; INTERLEUKIN 10; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ADULT; AMNION CELL; ARTICLE; ASYMPTOMATIC INFECTION; CHORION; CLINICAL ARTICLE; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; CYTOTROPHOBLAST; FEMALE; FETUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; LYMPH VESSEL ENDOTHELIUM; MATERNAL BLOOD; NEWBORN; NONHUMAN; PILOT STUDY; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UMBILICAL CORD BLOOD; VIRUS REPLICATION; VIRUS TRANSMISSION;

AMNION; BLOOD VESSELS; CHORION; CONGENITAL; FETUS; HCMV; IUGR; PLACENTA; PREGNANCY; VILLI;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; FETAL GROWTH RETARDATION; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEROLOGIC TESTS;

EID: 84897911317     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu019     Document Type: Article

References (50)

1. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis 2007; 7:71.
2. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 1986; 256:1904-8.
3. Pass RF, Fowler KB, Boppana SB, Britt WJ, Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 2006; 35:216-20.
4. Enders G, Daiminger A, Bader U, Exler S, Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 2011; 52:244-6.
5. Garcia AG, Fonseca EF, Marques RL, Lobato YY. Placental morphology in cytomegalovirus infection. Placenta 1989; 10:1-18.
6. Muhlemann K, Miller RK, Metlay L, Menegus MA. Cytomegalovirus infection of the human placenta: an immunocytochemical study. Human Pathol 1992; 23:1234-37.
7. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008-11.
8. Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Virol 2000; 74:6808-20.
9. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 2006; 168:1210-26.
10. Pereira L, Maidji E, McDonagh S, Genbacev O, Fisher S. Human cytomegalovirus transmission fromthe uterus to the placenta correlates with the presence of pathogenic bacteria and maternal immunity. J Virol 2003; 77:13301-14.
11. McDonagh S, Maidji E, MaW, Chang HT, Fisher S, Pereira L. Viral and bacterial pathogens at the maternal-fetal interface. J Infect Dis 2004; 190:826-34.
12. McDonagh S, Maidji E, Chang HT, Pereira L. Patterns of human cytomegalovirus infection in term placentas: a preliminary analysis. J Clin Virol 2006; 35:210-5.
13. Maidji E, Nigro G, Tabata T, et al. Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol 2010; 177:1298-310.
14. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353:1350-62.
15. Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99: 490-6.
16. Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology 1991; 181: 129-33.
17. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 1993; 197:143-58.
18. Gerna G, Sarasini A, Patrone M, et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 2008; 89:853-65.
19. Ilic D, Kapidzic M, Genbacev O. Isolation of human placental fibroblasts. Curr Protoc Stem Cell Biol 2008; 5:1C.6.1-1C.6.17.
20. Dondero DV, Pereira L. Monoclonal antibody production. In: Emmons RSchmidt N, eds. Diagnostic procedures for viral, rickettsial and chlamydial infections. Washington, DC. American Public Health Association, 1990:101-24.
21. Nozawa N, Fang-Hoover J, Tabata T, Maidji E, Pereira L. Cytomegalovirus-specific, high-avidity IgG with neutralizing activity in maternal circulation enriched in the fetal bloodstream. J Clin Virol 2009; 46 (Suppl 4):S58-63.
22. Bodeus M, Goubau P. Predictive value of maternal-IgG avidity for congenital human cytomegalovirus infection. J Clin Virol 1999; 12:3-8.
23. Revello MG, Zavattoni M, Baldanti F, Sarasini A, Paolucci S, Gerna G. Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. J Clin Virol 1999; 14:57-66.
24. Daiminger A, Bader U, Enders G. Pre-and periconceptional primary cytomegalovirus infection: risk of vertical transmission and congenital disease. BJOG 2005; 112:166-72.
25. Revello MG, Genini E, Gorini G, Klersy C, Piralla A, Gerna G. Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays. J Clin Virol 2010; 48:255-9.
26. Enders G, Daiminger A, Bader U, Exler S, Schimpf Y, Enders M. The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy. J Clin Virol 2013; 56:102-7.
27. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
28. Yamamoto-Tabata T, McDonagh S, Chang HT, Fisher S, Pereira L. Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro. J Virol 2004; 78: 2831-40.
29. Tabata T, Kawakatsu H, Maidji E, et al. Induction of an epithelial integrin alphavbeta6 in human cytomegalovirus-infected endothelial cells leads to activation of transforming growth factorbeta1 and increased collagen production. Am J Pathol 2008; 172:1127-40.
30. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-83.
31. Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 2011; 203:1526-33.
32. Syridou G, Spanakis N, Konstantinidou A, et al. Detection of cytomegalovirus, parvovirus B19 and herpes simplex viruses in cases of intrauterine fetal death: association with pathological findings. J Med Virol 2008; 80:1776-82.
33. Pereira L. Have we overlooked congenital cytomegalovirus infection as a cause of stillbirth?. J Infect Dis 2011; 203:1510-2.
34. Redline RW, Pappin A. Fetal thrombotic vasculopathy: the clinical significance of extensive avascular villi. Hum Pathol 1995; 26:80-5.
35. Atzmony L, Halutz O, Avidor B, et al. Incidence of cytomegalovirusassociated thrombosis and its risk factors: a case-control study. Thromb Res 2010; 126:e439-43.
36. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 2:644-7.
37. Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994; 42:170-4.
38. Hendrix MG, Daemen M, Bruggeman CA. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol 1991; 138:563-7.
39. Tumilowicz JJ, Gawlik ME, Powell BB, Trentin JJ. Replication of cytomegalovirus in human arterial smooth muscle cells. J Virol 1985; 56:839-45.
40. Bodeus M, Kabamba-Mukadi B, Zech F, Hubinont C, Bernard P, Goubau P. Human cytomegalovirus in utero transmission: follow-up of 524 maternal seroconversions. J Clin Virol 2010; 47:201-2.
41. Revello MG, Fabbri E, Furione M, et al. Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience. J Clin Virol 2011; 50:303-7.
42. Gillaux C, Mehats C, Vaiman D, Cabrol D, Breuiller-Fouche M. Functional screening of TLRs in human amniotic epithelial cells. J Immunol 2011; 187:2766-74.
43. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311:1-16.
44. Kjaergaard N, Hein M, Hyttel L, et al. Antibacterial properties of human amnion and chorion in vitro. Eur J Obstet Gynecol Reprod Biol 2001; 94:224-9.
45. Kim YM, Romero R, Chaiworapongsa T, et al. Toll-like receptor-2 and-4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol 2004; 191:1346-55.
46. Boehme KW, Guerrero M, Compton T. Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006; 177:7094-102.
47. Stone DL, Suzuki Y, Wood GW. Human amnion as a model for IgG transport. Am J Reprod Immunol Microbiol 1987; 13:36-43.
48. Adler SP. Editorial commentary: primary maternal cytomegalovirus infection during pregnancy: do we have a treatment option? Clin Infect Dis 2012; 55:504-6.
49. Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 2012; 55:497-503.
50. Nigro G, Adler SP, Parruti G, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy-a case-control study of the outcome in children. J Infect Dis 2012; 205:215-27.